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A b s t r a c t  
The objective of present work was to formulate and evaluate bilayered tablets of Levocetrzine and 
Montelukast for treating allergic rhinitis effectively. Anti-allergic medicines (eg, some antihistamines) 
can cause adverse events such as somnolence and sedation. The Combining Montelukast with 
Levocetirizine gives additional benefits in comparison with either drug alone and could be 
considered for patients whose quality of life is impaired by persistent allergic rhinitis. Montelukast 
sodium is alkaline stable (bioavailability 64%), most of drug being absorbed from the intestine while 
Levocetirizine Dihydrochloride is acid stable. When tablets of the combination of these are  
prepared, they tend to become unstable during the shelf life of the formulation. Hence it is 
recommended to prepare a bilayer tablet, by formulating Montelukast in sustained release layer and 
Levocetrizine as immediate release layer as it improves and increases the stability by reducing the 
acid base interactions of both the drugs in combination there by increasing the bioavailability. Taking 
this into account different formulations were prepared by wet granulation method using natural 
Tamarind Seed Polysaccharide and synthetic HPMCK100,K15M and K4M release rate controlling 
hydrophilic polymers. The formulations were evaluated for hardness, weight variation, friability, 
swelling index and drug content uniformity. The in vitro release of drug from the formulations was 
studied in pH 1.2 acidic buffer and pH 7.4 phosphate buffer, and it was found that the prepared 
tablets were able to sustain the release of the drug upto 12hours. The release of Montelukast and 
Levocetrizine of both layers from the tablets was found to be diffusion controlled and the release 
mechanism was non-Fickian based on the n value of Korsmeyer-peppas plot. The FTIR studies 
were performed on three optimized formulations (F4, F12, F16) and the plain drug 
controls(Levocetrizine,Montelukast).From the  observed peaks it is evident that the polymers used 
and the drugs were  found to be mutually compatible chemically. The Pharmacokinetic Studies were 
performed in two groups of male wistar rats. One group was administered with the optimized 
formulation containing tamarind Seed Polysaccharide(F12) while Plain Montelukast oral suspension 
acted as control in the second group.The results indicate that the formulation optimised with 
1:4(drug:TSP) was able to sustain the release of montelukast upto 12hours.Insrease in Tmax and 
AUC(0-α) also were also observed in the studies indicating efficient sustained action and improved 
bioavailability of the drug. The formulated bilayered tablets using natural polymers provided 
immediate release of Levocetrizine and sustained release of Montelukast and therefore hold promise 
as an alternative dosage form in the treatment of allergic rhinitis and bronchial asthma. 
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Introduction 
The preferred treatment option in the treatment  of chronic 
diseases i.e hypertension, diabetes and allergic rhinitis is 
combination therapy in the form of bilayer tablets. The advantages 





related risk. Using low dosage of two different agents minimizes 
the clinical and metabolic effects that may occur with higher doses 
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Bilayered tablets are tablets containing subunits that may be 
either the same (homogeneous) or different (heterogeneous). 
Bilayer tablets are prepared with one layer of drug for immediate 
release and second layer designed to release the drug as a 
second dose or for extended release. These tablets are suitable 
for sequential release of two drugs in combination, separate two 
incompatible substances and when the release profiles of the two 
drugs are different from one another[4]. Levocetirizine 
dihydrochloride  is  a  selective,  long  acting  peripheral  H1 
receptor antagonist. Allergic rhinitis is a symptomatic disorder of 
the nose induced by inflammation mediated by immunoglobulin 
E (IgE) in the membrane lining the nose after allergen exposure. 
Formulating Levocetirizine into an immediate release layer 
dosage of bilayer tablets would provide fast relief . 
Montelukast is a leukotriene receptor antagonist (LTRA) used for 
the maintenance treatment of asthma attacks and to relieve 
symptoms of seasonal allergies. Because of poor bioavailability of  
Montelukast sodium by oral route(mainly absorbed by 
intestine)and it shorter half life of (t1/2=2to5hours), there is a need 
to increase its bioavailability by formulating as a sustained release 
layer in the bilayer tablets to prevent frequent administration.  
In formulation of immediate release layer of  Levocetizine super 
disintegrants like Sodium starch glycolate and Croscarmellose 
were used. The sustained release layer of Montelukast was 
formulated using  hydrophilic polymers (Tamarind  seed 
polysaccharide, HPMC K100M,K15M and  K4M). 
The aim of the present study was to design and evaluate bilayer 
tablets of Montelukast and Levocetrizine for the treatment of 
allergic rhinitis. The immediate release layer was fabricated  to 
release  levocetrizine within 30min into the stomach and the 
second layer for the  sequential release of Montelukast in small 
intestinal for sustained action .Swelling studies and Invivo studies 
were performed for sustained release layer  containing  Tamarind 
seed polysaccharide. The results indicated that the formulated 
bilayered tablets using natural polymers provided immediate 
release of Levocetrizine and sustained release of Montelukast. 
Materials and methods  
Materials: 
Levocetrizine dihydrochloride was a kind gift from Symed labs, 
Hyderabad, India, Montelukast sodium was a kind gift sample 
from Matrix laboratories, Hyderabad, India. Hydroxy propyl methyl 
cellulose was purchased from Colocron Asia Pvt limited India. 
Poly Vinyl Pyrollidine (PVP)K90D was a kind gift sample from 
Dr.Reddy’s Laboratories,Hyderabad. All the solvents used were of 
HPLC grade purchased from Merck Chemicals,India. 
Methods: 
Isolation of Tamarind seed polysaccharide(TSP): 
Tamarind seed polysaccharide (TSP) was isolated by the method 
reported by Rao et al [5].  To 20g of tamarind kernel powder, 
200ml of cold distilled water was added and slurry was prepared. 
The slurry was poured into 800ml of boiling distilled water. The 
solution was boiled for 20 minutes under Stirring condition in a 
water bath. The resulting thin clear solution was kept overnight so 
that most of the proteins and fibers settled out. The solution was 
then centrifuged at 5000 rpm for 20 minutes. The supernatant was 
separated and poured into twice the volume of absolute ethanol 
by continuous stirring. The product was filtered through muslin 
cloth and was pressed between felt. The precipitate was washed 
with absolute ethanol, iso-propanol and methanol and then dried 
at 50-60ºC in hot air oven for 24 hours. The dried material was 
ground and sieved to obtain granules of different particle size 
range and stored in a desiccator until further use. 
Preparation of bilayer tablets 
Immediate release layer:  
Levocetrizine tablets were prepared by wet granulation method. 
Levocetrizine, super disintegrants (Sodium starch glycolate, 
croscarmellose) and lactose were weighed as in Table1 and 
mixed thoroughly. Starch Paste (5%) was used as a Binder. The 
wet mass was passed through sieve no 12. The obtained 
granules were dried at 40°C for 30min in tray drier. The dried  
granules were screened through sieve no 22 and later using sieve 
no.44  Magnesium stearate(1%) and talc(q.s) were used for 
lubrication. 
Sustained release layer: 
Montelukast sodium tablets were also prepared by wet 
granulation method. Specified quantity of drug, polymer 
(Tamarind Seed Polysaccharide, HPMC Grades K100M, K15M, 
and K4M.) and Microcrystalline celluose were weighed as in Table 
2 and mixed thoroughly. PVP (1%) was used as binder. Granules 
were obtained by passing the sluggy mass through sieve no 12. 
The prepared granules were dried at 40°C in a tray drier for 1 
hour. The dried granules were screened through sieve no 22. 
Magnesium stearate(1%) and Talc(q.s) were finally added  and 
mixed by triangular mixing. These lubricated granules were 
compressed into tablets weighing about 250 mg containing 75 mg 
of Levocetrizine and 175mg Montelukast in a Rotary tablet 
compression machine (12 station, RIMEK, India) using 9 mm 
circular, flat punches plain on both sides .The compressed tablets 
were stored in HDPE containers for stability studies.  
Evaluation of both immediate release and sustained 
release granules: 
Flow properties [6-8] 
Bulk Density (Db): It is the ratio of total mass of powder to the bulk 
volume of powder. It was measured by pouring the weighed (25 
grams) powder (passed through standard sieve # 20) into a 100ml 
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measuring cylinder and initial weight will be noted. This initial 
volume is called bulk volume. From this the bulk density was 
calculated according to the formula mentioned below. It is 
expressed in g/ml and is given by 
 
Bulk Density (g/ml) = Mass of the powder/Bulk Volume 
Tapped Density (Dt): It is the ratio of total mass of the powder to 
the tapped volume of the powder. Volume was measured by 
tapping the powder for 750 times and the  volume was  noted, if 
the difference between these two volumes is less than 2%. If it is 
more than 2%, tapping was continued for 1250 times and tapped 
volume was noted. Tapping was continued until the difference 
between successive volumes is less than 2 % (in a bulk density 
apparatus). It is expressed in g/ml and is given by 
 
Tapped density (g/ml) = Mass of the powder/Tapped volume 
 
Angle of Repose (ө): The friction forces in a loose powder can be 
measured by the angle of repose (ө). It is an indicative of the flow 
properties of the powder. It is defined as maximum angle possible 
between the surface of the pile of powder and the horizontal 
plane. The powder mixture was allowed to flow through the funnel 
fixed to a stand at definite height (h). The angle of repose was 
calculated by measuring the height and radius of the heap of 
powder formed. 
                                                 ө = tan-1 (h / r) 
Where, ө - angle of repose,  h- height in cms,  r -radius in cms 
 
Carr’s index (or) % compressibility: It indicates powder flow 
properties. It is expressed in percentage and is given by 
 
Carr’s Index (%) = [(Tapped density – Bulk Density) / Tapped 
Density] × 100 
 
Hausner ratio: Hausner ratio is an indirect index of ease of 
powder flow. It is calculated by the following formula. 
Hausner’s Ratio = Tapped density / Bulk Density 
 
Evaluation of bilayer tablets of Montelukast and 
Levocetrizine dihydrochloride[9]:  
Hardness: The hardness of the tablet was measured by Monsanto 
hardness tester. The lower plunger was placed in contact with the 
tablet and a zero reading was taken. The plunger was then forced 
against a spring by tuning a threaded bolt until the tablet 
fractured. As the spring was compressed a pointer rides along a 
gauge in the barrel to indicate the force. The hardness was 
measured in terms of kg/cm2. 
Weight variation: Formulated matrix tablets were tested for weight 
uniformity, 20    tablets were weighed collectively and individually. 
From the collective weight, average weight was calculated. The 
percent weight variation was calculated by using the following 
formula. 
                        
  
Friability: The Roche friability test apparatus was used to 
determine the friability of the tablets. Twenty pre-weighed tablets 
were placed in the apparatus and operated for 100 revolutions 
and then the tablets were reweighed. The percentage friability 
was calculated according to the following formula. 
                               
 
Swelling characteristics (water uptake study)[10] 
The swelling properties of HPMC matrices containing drug were 
determined by placing the tablet matrices in the dissolution test 
apparatus, in 900 ml of 7.4PBS at 37 ± 0.5 0C. The tablets were 
removed periodically from dissolution medium. After draining free 
from water by blotting paper, these were measured for weight 
gain.Swelling characteristics were expressed in terms of 
percentagewater uptake (WU %) show relationship between 
swelling index and time.28‐30 
 
 
                            
Drug content:  
 Drug content of Levocetrizine layer : 
Ten tablets of each formulation were weighed and powdered. A 
quantity of powder equivalent to 5 mg of Levocetirizine 
dihydrochloride was taken into 50 ml volumetric flask. The amount 
of drug present in a 5 mg equivalent amount of powder was 
determined by dissolving the powder mixture in 10ml of methanol 
and UV absorbance was measured at 231nm.  
Drug content of Montelukast layer: 
Ten tablets of each formulation were weighed and powdered. A 
quantity of powder equivalent  to 10 mg of Montelukast was taken 
into 50 ml volumetric flask. The amount of drug present in a 10 
mg equivalent amount of powder was dissolved in 0.5% SLS 
solution. The volume of this solution(2ml) was taken and diluted 
100
 WeightInitial
 WeightFinal  - Weight Initial
    Friability X=
 WeightAverage 
   Weight Average
  Variation  Weight % = 
- Individual Weight
                         Weight of swollen tablet – Initial weight of the tablet 
                WU % =  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ x 100 
                                             Initial weight of the tablet 
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with water up to 10ml with methanol . UV absorbance was 
measured at 344 nm.  
In vitro drug release studies  
The release of drug from different batches of prepared tablets was 
studied by using USP dissolution apparatus type II [11]. Buffer 
was used as dissolution medium pH 1.2 for 2 h and phosphate 
buffer of pH 7.4for 12 h. The medium volume was maintained at 
900ml, the temperature was maintained at 37°C ± 0.5°C and the 
stirring rate was 50 RPM. Samples were withdrawn at regular time 
intervals and the same volume was replaced with fresh dissolution 
medium. The samples were measured by UV Spectrophotometer 
at 231 nm for immediate release layer Levocetrizine and 
Montelukast at 344nm for sustained release layer against a blank.  
Predicting Mechanism of drug release 
Various models were tested for explaining the kinetics of drug 
release. 
To analyze the mechanism of the drug release rate kinetics of the 
dosage form, the obtained data was fitted in to zero order, first 
order, Higuchi and Korsmeyer-Peppas release model, to study the 
drug release from the dosage form 
 
Zero order release rate kinetics:- 
To study the zero—order release kinetics the release data are 
fitted to the following equation. 
           F=Ko .t 
Where ‘F’ is the drug release, ‘K’ is the release rate constant 
and’t’ is the release time. The plot of %drug release versus time is 
linear. 
 
First order release kinetics:  
The release rate data are fitted to the following equation. 
                     Log (100-F)= kt 
  A plot of log % drug release versus time is linear. 
 
Higuchi release model: 
To study the Higuchi release kinetics, the release rate data were 
fitted to the following equation, 
        F= k t1/2 
Where ‘k’ is the Higuchi constant 
In Higuchi model, a plot of % release versus square root of time is 
linear. 
 
Korsemeyer and Peppas release model: 
The release rate data were fitted into the following equation, 
Mt / Mα = K.tn 
Where Mt / Mα   is the fraction of drug released,  
‘K’ is the release constant, 
‘t ‘ is the release time. 
‘n’ is diffusion exponent, if n is equal to 0.89 the release is zero 
order, if n=0.45 the release is best explained by Fickian diffusion, 
and if 0.45<n<0.89 then the release through anomalous diffusion 
or non-fickian diffusion (Swellable and Cylindrical matrix). 
In this model a plot of log (Mt / Mα ) versus log(time) is linear. 
The drug release data of optimized bilayer tablets were fitted to 
zero order, first order, Higuchi and Korsmeyer-Peppas model to 
study the kinetics of drug release. 
In vivo Evaluation [12,13]: 
Male rats weighing 150-250grams shall be selected. Rats shall be 
divided into 2groups (n=2).The animals shall be  housed  
individually at (25ºC, 12 h light and dark cycle). The rats shall be 
fasted overnight and allowed free accesses to water only. The 
optimized formulation were   administered to one group and 
marketed formulation were administered to other group orally by 
using gastric intubation method .  Samples of blood shall be 
withdrawn at predetermined time interval from  reteroorbital 
plexus. The Institutional Animal Ethical Committee approved the 
protocol for this study bearing no SVCP/IAEC/2011/08. 
Sample preparation: 
 Samples of blood were withdrawn at predetermined time intervals 
from retro orbital plexus.  The collected blood was centrifuged at 
2000 rpm for 10 minutes to obtain the plasma. To 200μl of plasma 
sample, 750μl of acetonitrile was added. The mixture was vortex-
mixed on a vortex mixer for five minutes and then centrifuged at 
13000 rpm for 5.0min .After centrifugation, the supernatant was 
transferred to glass tubes with caps .Analysis was carried out by 
injecting  20 μl of this sample into the HPLC system.  
HPLC Assay 
The samples analyzed using HPLC with Reverse Phase stainless 
steel C18(2) column250x4.60mm,5µm dimensions The mobile 
phase was prepared using Acetonitrile: potassium dihydrogen 
phosphate (0.05 M (70:30v/v) adjusted to pH 3.5 ± 0.1 with Ortho 
Phosphoric acid. Flow rate was maintained at 2.0 ml/min. The 
samples were analyzed at 344 nm.  
 Results & discussion  
Characterization of Levocetrizine and Montelukast 
immediate bilayered tablets. 
 Pre-compression parameters  
The Levocetrizine and Montelukast granules were prepared by 
wet granulation method. The prepared granules of different 
batches were evaluated for their granule size, angle of repose, 
bulk density, tapped density, compressibility index and Hausner’s 
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ratio, as shown in Table 3 and 4. The granules have an average 
size in the range of 0.448 ± 0.11 to 0.683 ± 0.15 mm, which 
indicates narrow size distribution. The bulk densities of the 
granules were found to be in the range of 0.400 to 0.48 gm/ml. 
The angle of repose varied from 27.51 ± 0.18 to 31.37 ± 0.18. The 
low values of angle of repose indicate the free flowing nature of 
the granules. The tapped densities ranged 0.444 to 0.545 gm/ml 
and the Carr’s indexes were in the range of 9.05 to 13.53. 
Hausner’s ratio was found in the range of 1.02 ± 0.04 to 1.15 ± 
0.09 and the values showed the low interparticle friction between 
the granules. 
Post-compression parameters 
The bilayer tablets of Montelukast and Levocetrizine were 
prepared by wet granulation method. The prepared tablets were 
evaluated for their weight variation, hardness, friability and drug 
content uniformity, and the results are presented in Table 5and 6. 
The values were found to be within the prescribed limits varied 
between 0.09 ± 0.024 to 1.4 ± 0.02 %. Hardness was in the range 
of 4.5 ± 0.14 to 7.7 ± 0.35 kg/cm2. Friability was found to be less 
than 1% in all the batches which indicates the ability of the 
prepared tablets to withstand shock during the time of 
transportation and handling. Drug content was uniform within the 
prepared batches and ranged between 72.87 ± 0.34 to 96.84 ± 
0.16%. 
Swelling index: 
The swelling index was calculated with respect to time. With 
increasing time, the swelling index was increased. This is 
because of the weight gain by tablets proportionally with 
increased rate of hydration. After 3hours a gradual decrease in 
the swelling index was seen due to dissolution of outermost gelled 
layer of tablet into dissolution medium. A direct relationship was 
observed between swelling index and Tamarind Seed 
Polysaccharide concentration as seen in Fig 1 and 2.  From the 
Fig 1 it is clear that the matrices underwent swelling in the 
dissolution media almost immediately. From the results it can be 
seen that the release profile of the drug is influenced by this 
swelling. A constant release is observed here due to the increase 
in diffusional path length caused by swelling, which is 
compensated by continuous erosion of the matrix. 
Cumulative percentage release profiles of LEVO layer 
of various formulations using SSG and CCS: 
The quantitative formula of each of the formulations using 
different superdisintegrants is given in Table 1.The drug release 
data of various formulations using different superdisintegrants is 
graphically represented in Fig 3 and Fig 4. The percentage drug 
released for the formulations F1, F2 and F3 was found to be more 
than 90% after 30 minutes. With the increase in the concentration 
of  SSG from 1.5mg to 3.75mg a gradual increase in the drug 
release is observed.However with F4(3.75mg) ,more than 95% 
drug release was achieved in 25minutes 
The comparative in vitro release profile is depicted in Fig 4. The 
percentage drug released for the formulations F5 and F6 were 
found to be more than 90% after 30 minutes. With the increase in 
the concentration of CCS from 1.5 mg to 3.75mg a gradual 
increase in the drug release is observed. However with F7 (3mg) 
and F8 (3.75mg) more than 95% drug release was achieved in 25 
minutes .  
Cumulative percentage release profiles of MONT layer 
of various formulations using TSP and HPMC grades: 
The quantitative formulae of various preparations using different 
polymers in different concentrations is depicted in Table 2.The 
release rate of Montelukast was found to be effected by the 
concentration of the polymer used in the preparation of tablets.A 
decrease in release rate was observed by increase in TSP 
concentration. The release rate for optimized formulation (F12) 
showed release up to 12hours. The influence of polymer 
concentration on drug release, formulations (F14-F28) using 
different concentrations of HPMC K100M, HPMC K15M and 
HPMC K4M is shown in Fig 6 and Fig 7. At 1:3 drug to polymer 
ratio, HPMC K100 showed release up to 12hours whereas in case 
of K15M, 1:4 ratio was optimized. In case of K4M the sustained 
action could be seen only at 5parts of the polymer as seen in Fig 
8. With the increase in viscosity of HPMC grades, a retarding 
effect on the drug release was observed.  
Release kinetics  
The in vitro release data obtained from Formulations F1-F8 using 
different concentrations of SSG and CCS was fitted to kinetic 
models such as zero order, first order, Higuchi and Korsmeyer-
Peppas models [14] to explore the release mechanism and the 
values are given in Table 7 and 8. The cumulative percentage 
drug released was found to be in the order of F4>F3>F2>F1 in 
case of SSG formulations. The values of release exponents ‘n’ for 
these formulations were found to be 0.514, 0.531,0.463 and 0.471 
respectively indicating the release is governed by non-Fickian 
anomalous transport. The values of release exponents ‘n’ for CCS 
formulations F5, F6, F7 and F8  were found to be 0.578, 0.631, 
0.584 and 0.544 respectively indicating the release is governed by 
non-Fickian anomalous transport. 
The in vitro release data of optimized formulations F12, F16, F22 
and F28 using TSP and HPMC grades was fitted to kinetic models 
such as zero order, first order, Higuchi and Korsmeyer-Peppas 
models [13] to explore the release mechanism and the values are 
given in Table 9. The data obtained from the release kinetics fitted 
with Higuchi model indicated that the release of drug from the 
tablets was found to depend on the square root of time. Further, it 
is important to note that a linear relationship was obtained for a 
plot of release profile verses time, and the regression coefficient 
was very close to zero (R2 = 0.995, 0.987, 0.979 and 0.981)for 
these formulations respectively. The n values obtained from the 
Korsmeyer-Peppas model showed that the release mechanism 
was non-Fickian [15]. 
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Accelerated Stability studies: 
The data of Stability studies  of batch F12 is given in Tables 11 
and 12.The studies indicate  no  change in physical appearance 
of tablets over a period of three months in accelerated 
conditions(40°C/75 % RH). The results of stability study after three 
months, cumulative percentage drug release of batch F12 shows 
95.89% for LEVO layer and 98.61% for the MONT layer in 
3months. 
Drug - Excipient compatibility studies: 
The FTIR studies of pure drugs LEVO and MONT ,the natural 
polymer TSP  and optimized formulations (F12) were carried out 
to detect any major interfering incompatibility between the drugs 
and the polymer . Few FTIR stectra are given in Fig 9, 10, 11 and 
the data is given in  
Tables 13. 
The absorption peaks of tamarind seed polysaccharide were 
found at 1036 cm-1 (C-O-C, ether group absorbance), 1637 and 
1655 cm-1 (C=O, aldehyde absorption), 2924 cm-1 (C-H 
stretching), 3356 cm-1 (primary OH), 3385  cm-1 (secondary OH), 
which indicate that isolated product was polysaccharide. There is 
no change in shift of major peaks of drug (C=O str, C=H str , OH-
str) observed.  
In vivo studies:  
In vivo studies were carried out to evaluate the pharmacokinetic 
behavior of the optimized F12 formulation. The sample 
chromatograms of the studies are given in Fig 15 - 17.The 
retention time of Montelukast is 5.5. 
Quantification and Linearity: 
The plasma standard curves were prepared over the range of 50-
250µg/ml. The calibration curves of MONT were typically 
described by the regression analysis equation Y=169.6x+0.997. 
Plasma concentration and pharmacokinetic parameters after oral 
administration of formulated sustained release layer bilayer tablet 
and plain drug are summarized in Table 14 and Figure 15. From 
the data, the control preparations have shown immediate release 
upto 6 hours.Significantly higher plasma concentrations were 
seen after 90min of dose administration, but were found to decline 
rapidly. It is important to note that the formulated Sustained 
release bilayer tablets (Code F12) showed significantly higher 











These tablets also maintained constant plasma concentrations up 
to 12 hours. The improvement in the blood levels indicate that the 
bilayered tablets made from TSP are therapeutically more 
effective in the treatment of bronchial asthma. A four-fold increase 
in AUC was observed in case of bilayered tablets when compared 
to the plain drug data. The increase in AUC indicates 
improvement in the bioavailability due to the bilayered tablets. It is 
interesting to note that the T max has increased from 3 hrs(control) 
to 6 hrs in case of our F12 formulation indicating slow and 
constant release of the drug contributing to sustained 
action.Overall the preliminary pharmacokinetic data suggest that 
the F12 formulation is a suitable canditate in providing sustained 
drug levels of MONT upto 12hours. 
Conclusion 
The prepared bilayered tablets of Montelukast and Levocetrizine 
DiHydrochloride using sodium starch glycolate and 
Croscarmellose sodium showed immediate release of 
Levocetrizine layer in 25min (F4 and F8). The second layer 
formulated using Tamarind seed polysaccharide(F 12) showed 
sustained release up to 12 hours compared to the formulations 
(F16, F22, F28)  using HPMC Grades (K100M, K15M, K4M). 
From the stability studies Bilayered tablets with tamarind seed 
polysaccharide were found to be stable. The formulated 
Sustained release bilayered tablets (F12) showed significantly 
higher Cmax (74.7μg) compared to control formulations. The 
plasma concentrations remained constant up to 12 hours.The 
AUC of F12 was found to show a four fold increase compared to 
the control indicating improvement in the bioavailability. The tmax 
of the formulated F12 tablets was found to be doubled indicating 
slower and sustained release of the formulated tablets.Hence 
from our investigations we can conclude that the bilayered tablets 
of LEVO and MONT prepared using TSP are a promising 
alternative in the effective treatment of patients suffering from 
Allergic rhinitis and bronchial asthma.  
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Fig 2: Comparative profile of swelling index with that of Tamarind Seed Polysaccharide 
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Fig 3:  In vitro release profiles of immediate release layer for bilayer tablets of   








Fig 4. In vitro release profile of immediate release layer for  bilayer  tablets of Levocetrizine 
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Fig.6.Invitro release profile of sustained release layer of formulation withHPMCK100M 
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Fig.7.Invitro release profile of sustained release layer of formulation with HPMCK15M 
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Fig.9: FTIR spectrum of pure drug montelukast 
 
 
Fig.10: FTIR spectrum  of tamarind seed polysacharide 
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Fig.11: FTIR spectrum of optimised formulation (F12) 
 
 
Fig.12.Chromatogram of plain plasma 
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Fig.13.Chromatogram of control sample 12hours after drug administration 
 
Fig.14.Chromatogram of test sample 12hours after drug administration 
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Fig 15.  Plasma concentration-time profiles of optimized batch of Sustained Release layer 
Bilayer tablet (batch F12) and Control plain drug after oral administration. 
 
 




















F1 5 1.50 - 67.00 q.s 0.75 0.75 75 
F2 5 2.25 - 66.25 q.s 0.75 0.75 75 
F3 5 3.00 - 65.50 q.s 0.75 0.75 75 
F4 5 3.75 - 64.75 q.s 0.75 0.75 75 
F5 5 - 1.50 67.00 q.s 0.75 0.75 75 
F6 5 - 2.25 66.25 q.s 0.75 0.75 75 
F7 5 - 3.00 65.50 q.s 0.75 0.75 75 
F8 5 - 3.75 64.75 q.s 0.75 0.75 75 
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Table 2. Formulation and optimisation of Montelukast sustained release layer 
Mont-Montelukast, TSP- Tamarind seed polysaccharide  
HPMC - Hydroxypropyl methylcellulose (K100M,K-15M,K4M);  
MCC- Microcrystallinecellulose(101);PVP-Polyvinylpyrollidine  




























F9 10 10 - -  146 q.s 6 3 175 
F10 10 20 - -  136 q.s 6 3 175 
F11 10 30 - -  126 q.s 6 3 175 
F12 10 40 - -  116 q.s 6 3 175 
F13 10 50 - -  106 q.s 6 3 175 
F14 10 - 10 -  146 q.s 6 3 175 
F15 10 - 20 -  136 q.s 6 3 175 
F16 10 - 30 -  126 q.s 6 3 175 
F17 10 - 40 -  116 q.s 6 3 175 
F18 10 - 50 -  106 q.s 6 3 175 
F19 10 - - 10  146 q.s 6 3 175 
F20 10 - - 20  136 q.s 6 3 175 
F21 10 - - 30  126 q.s 6 3 175 
F22 10 - - 40  116 q.s 6 3 175 
F23 10 - - 50  106 q.s 6 3 175 
F24 10 - - - 10 146 q.s 6 3 175 
F25 10 - - - 20 136 q.s 6 3 175 
F26 10 - - - 30 126 q.s 6 3 175 
F27 10 - - - 40 116 q.s 6 3 175 
F28 10 - - - 50 106 q.s 6 3 175 
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F-1  0.40 ± 0.06  0.444 ± 0.05  10.01 ± 0.14  1.11 ± 0.06  29.05 ± 0.25 
F-2  0.480 ± 0.03  0.545 ± 0.03  11.92 ± 0.12  1.13 ± 0.02  29.74 ± 0.24 
F-3  0.440 ± 0.04  0.500 ± 0.02  12.00 ± 0.15  1.13 ± 0.05  27.75 ± 0.15 
F-4  0.432 ± 0.05  0.490 ± 0.04  11.83 ± 0.13  1.13 ± 0.03  29.74 ± 0.17 
F-5  0.416 ± 0.03  0.476 ± 0.05  12.60 ± 0.09  1.14 ± 0.04  29.05 ±0.26  
F-6  0.409 ± 0.04  0.473 ± 0.03  13.53 ± 0.24  1.15 ± 0.09  29.30 ± 0.14 
F-7  0.412 ± 0.04  0.460 ± 0.05  10.43 ± 0.20  1.11 ± 0.07  29.60 ± 0.34 
F-8  0.420 ± 0.03  0.466 ± 0.06  9.87 ± 0.14  1.10 ± 0.06  28.52 ± 0.14 
*(n=3±SD)         














F-9  0.421 ± 0.05  0.476 ± 0.04  11.55 ± 0.07  1.13 ± 0.03  29.05 ± 0.26 
F-10  0.408 ± 0.03  0.450 ± 0.05  9.30 ± 0.17  1.10 ± 0.08  27.51 ± 0.18 
F-11  0.412 ± 0.05  0.454 ± 0.03  9.20 ± 0.23  1.07 ± 0.04  30.76 ± 0.21 
F-12  0.410 ± 0.02  0.463 ± 0.03  11.64 ± 0.18  1.12 ± 0.07  30.76 ± 0.36 
F-13  0.400 ± 0.02  0.444 ± 0.06  10.01 ± 0.32  1.11 ± 0.03  29.60 ± 0.12 
F-14  0.420 ± 0.03  0.474 ± 0.03  11.49 ± 0.12  1.12 ± 0.02  29.05 ± 0.24 
F-15  0.411 ± 0.05  0.456 ± 0.02  10.01 ± 0.15  1.10 ± 0.05  28.52 ± 0.15 
F-16  0.418 ± 0.05  0.472 ± 0.04  11.44 ± 0.13  1.12 ± 0.03  29.60 ± 0.17 
F-17  0.405 ± 0.03  0.450 ± 0.05  9.05 ± 0.09  1.06 ± 0.04  30.71 ± 0.26 
F-18  0.411 ± 0.04  0.455 ± 0.03  9.60 ± 0. 24  1.10 ± 0.09  29.05 ± 0.14 
F-19  0.430 ± 0.04  0.485 ± 0.05  11.34 ± 0.20  1.12 ± 0.07  29.60 ± 0.34 
F-20  0.415 ± 0.03  0.459 ± 0.06  9.50 ± 0.14  1.10 ± 0.06  28.52 ± 0.14 
F-21  0.411± 0.05  0.455 ± 0.04  9.60 ± 0.07  1.10 ± 0.03  28.00 ± 0.26 
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F-22  0.405 ± 0.03  0.457 ± 0.05  11.47 ± 0.17  1.12 ± 0.08  31.37 ± 0.18 
F-23  0.400 ± 0.05  0.451 ± 0.03  11.32 ± 0.23  1.12 ± 0.04  30.17 ± 0.21 
F-24  0.414 ± 0.02  0.457 ± 0.03  9.40 ± 0.18  1.10 ± 0.07  29.60 ± 0.36 
F-25  0.418 ± 0.02  0.472 ± 0.06  11.44 ± 0.32  1.12 ± 0.03  29.60 ± 0.12 
F-26  0.424 ± 0.07  0.477 ± 0.04  11.42 ± 0.06  1.13 ± 0.05  29.05 ± 0.07 
F27 0.420± 0.03 0.474 ± 0.03 11.49 ± 0.12 1.12 ± 0.02 29.05 ± 0.24 
F28 0.410 ± 0.02 0.463 ± 0.03 11.64 ± 0.18 1.12 ± 0.07 30.76 ± 0.36 
*(n=3±SD) 
 
Table 5. Physicochemical evaluations of Immediate release layer (Levocetrizine) Tablets  
Batch Code 
                                                  Parameter  




F-1  3.8 ± 0.4  0.012 ± 0.03  1.1 ± 0.05  91.23 ± 3.05  
F-2  4.4 ± 0.5 0.015 ± 0.02  1.4 ± 0.02  81.5 ± 2.21  
F-3  3.7 ± 0.33  0.010 ± 0.02  0.96 ± 0.01  78.2 ± 3.15  
F-4  4.7 ± 0.35   0.018 ± 0.03  0.859 ± 0.01  72.87 ± 4.34  
F-5  3.3 ± 0.21  0.005 ±0.03  0.09 ± 0.02  96.5 ± 2.42  
F-6  4.9 ± 0.15  0.020 ± 0.02  0.65 ± 0.03  96.84 ± 1.16  
F-7  4.7 ± 0.42  0.10 ± 0.02  0.43 ± 0.02  94.93 ± 3.09  
F-8  4.5 ± 0.17  0.12 ± 0.03  0.19 ± 0.02  92.87 ± 1.48  
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(kg/cm2 )*  
Friability (%)** Weight 
variation 
(%)** 
Drug content  
(%)  
F-9  4.4 ± 0.16  0.6 ± 0.04  0.29 ± 0.01  83.97 ± 2.26  
F-10  4.7 ± 0.24  0.40 ± 0.02  0.14 ± 0.01  91.36 ± 1.35  
F-11  3.9 ± 0.25  0.16 ± 0.02  0.56 ± 0.02  86.9 ± 2.42  
F-12  4.8 ± 0.34  0.27 ± 0.03  0.98 ± 0.02  94.15 ± 3.13  
F-13  4.0 ± 0.18  0.33 ± 0.03  0.132 ± 0.03  92.15 ± 3.18  
F-14  5.0 ± 0.29  0.33 ± 0.03  0.234 ± 0.04  86.15 ± 4.38  
F-15  6.5 ± 0.24  0.16 ± 0.02  0.287 ± 0.02  90.76 ± 2.27  
F-16  7.0 ± 0.18  0.16 ± 0.02  0.290 ± 0.01  86.72 ± 3.36  
F-17  5.0 ± 0.13  0.1 ± 0.01  0.76 ± 0.02  94.05 ± 2.15  
F-18  6.0 ± 0.25  0.4 ± 0.01  0.56 ± 0.04  92.00 ± 2.5  
F-19  5.5 ± 0.24  0.33 ± 0.05  0.54 ± 0.63  86.10 ± 4.04  
F-20  5.7 ± 0.13  0.27 ± 0.04  0.75 ± 0.03  89.76 ± 4.08  
F-21  6.5 ± 0.12  0.33 ± 0.01  0.76 ± 0.02  85.72 ± 4.04  
F-22  4.5 ± 0.14  0.33 ± 0.07  0.86 ± 0.04  94.15 ± 2.06  
F-23  5.0 ± 0.25  0.27 ± 0.01  0.56 ± 0.03  90.15 ± 2.07  
F-24  5.5 ± 0.12  0.33 ± 0.01  0.05 ±.0.02  86.15 ± 3.02  
F-25  6.0 ± 0.24  0.15 ± 0.01  0.3 ± 0.03  91.76 ± 2.05  
F-26  5.5 ± 0.05  0.16 ± 0.02  0.12 ± 0.02  86.72 ± 4.05  
F-27 6.0 ± 0.35 0.33 ± 0.05 0.54 ± 0.63 86.10 ± 4.04 
F-28 6.5 ± 0.44 0.16 ± 0.02 0.290 ± 0.01 86.72 ± 3.36 
*(n=6±SD)        **(n=20±SD)        ***(n=3 ±SD) 
 
Table 7. Swelling index of sustained release layer tablet with that of Tamarind Seed 
Polysaccharide (F9 T0 F13) 
 
Time F9 F10 F11 F12 F13 
0 0 0 0 0 0 
1 26.4    35.29 38.6 44.4 48.6 
2 44.3 52.14 55.6 55.6 57.9 
3 54.2 64.7 69.2 67.3 70.1 
4 44.3 52.94 54.4 78.2 80.2 
5 39.2 42.12 45.1 88.3 90.2 
6 34.2 39.2 38.1 76.6 91.2 
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Table 8: In vitro drug release kinetics of immediate release layer for  bilayer tablets of 
Levocetrizine DiHydrochloride  formulated with  SSG 
 
Formulation zero order r2 First order r2 Higuichi r2 Korsemeyer-peppas r2                   n 
F1 0.965 0.984 0.977 0.985              0.514  
F2 0.912 0.984 0.994 0996              0.531  
F3 0.879 0.958 0.978 0.998             0.463  
F4 0.909 0.947 0.988 0.995            0.471  
 
Table 9:   In vitro drug release kinetics of immediate release layer for  bilayer  tablets of 
Levocetrizine Di Hydrochloride  formulated with  Croscarmellose sodium 
 
Formulation zero order r2 First order r2 Higuichi r2 Korsemeyer-peppas r2              n 
F5 0.988 0.990 0.965 0.997            0.578  
F6 0.960 0.995 0.987 0.995            0.431  
F7 0.951 0.994 0.990 0.992            0.584  
F8 0.965 0.980 0.984 0.986            0.544  
 
Table 10: Release kinetics of Montelukast layer  of optimized  formulations. 
 
Formulation zero order r2 First order r2 Higuichi r2 korsemeyer-peppas r2               n 
F12 0.995 0.770 0.896 0.995         0.859 
F16 0.987 0.846 0.926 0.987         0.858 
F22 0.979 0.846 0.900 0.979        0.850 




Table 11: Cumulative % drug release of Immediate Release Layer stability study of F4 with 
sodium  starch glycollate. 
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Cumulative % Drug Released 
(After storage at 40°C after 3M) 
 
5 45.66 44.66 
10 58.83 57.99 
15 75.43 76.43 
20 90.83 89.83 
25 96.09 95.89 
30 - - 
 





Drug  Released 
(Initial) 
 
Cumulative % Drug Released 
(After storage at 40°C after 3 
month) 
0.5 4.01 3.91 
1 8.88 7.88 
1.5 11.76 11.76 
2 15.33 14.33 
3 20.54 20.54 
4 28.33 28.33 
5 38.43 37..43 
6 48.22 46.22 
7 55.11 55.11 
8 64.12 63.12 
9 77.98 77.98 
10 88.65 88.65 
11 96.44 95.44 
12 99.33 98.61 
 
TABLE 13: FTIR peak positions (cm-1) of Montelukast 
 
TYPE OF VIBRATION Frequency(cm-1) 
-OH 3417 
-C-H ar 2900-3100 
-C=O 1613 
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Table 14.Pharmacokinetic Parameters of Montelukast After Administration of control and 
Sustained Release Tablets 
 
Formulation Code AUC (μg/μL)*h Cmax (μg) tmax (hours) 
F12 0.562 74.7 6 
CONTROL 0.122 31.26 3 
 
